BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 11353053)

  • 21. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer.
    Amirghofran Z; Monabati A; Gholijani N
    Pathol Oncol Res; 2004; 10(1):37-41. PubMed ID: 15029260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
    Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
    J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
    Boltze C; Schneider-Stock R; Jäger V; Roessner A
    Pathol Res Pract; 2001; 197(8):563-8. PubMed ID: 11518050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
    Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
    Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
    Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.
    Hernandez I; Maddison LA; Wei Y; DeMayo F; Petras T; Li B; Gingrich JR; Rosen JM; Greenberg NM
    Mol Cancer Res; 2003 Dec; 1(14):1036-47. PubMed ID: 14707287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
    Zeng L; Rowland RG; Lele SM; Kyprianou N
    Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
    Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
    Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
    Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
    Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.
    Mirchandani D; Zheng J; Miller GJ; Ghosh AK; Shibata DK; Cote RJ; Roy-Burman P
    Am J Pathol; 1995 Jul; 147(1):92-101. PubMed ID: 7604888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
    Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
    Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease.
    Elenitoba-Johnson KS; Medeiros LJ; Khorsand J; King TC
    Am J Clin Pathol; 1996 Dec; 106(6):728-38. PubMed ID: 8980348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
    Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
    J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibiting effect of murine double minute-2 oncogene on apoptosis induced by retroviral-mediated wild-type p53.
    Guo H; Liu T; Gao J
    Chin Med J (Engl); 1998 Dec; 111(12):1102-6. PubMed ID: 11263374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
    Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
    Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
    Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.